![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
2C-Adrenoceptor Expression
in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects
of Dexmedetomidine, a Subtype-Nonselective
2-Adrenoceptor Agonist
Department of Pharmacology and Clinical Pharmacology, University of
Turku, FIN-20520 Turku, Finland (J.S., M.K., B.S., M.S.),
Orion
Corporation, Orion-Pharma, FIN-20101 Turku, Finland (A.H., T.V., T.L.),
Department of Pharmacology and Toxicology (E.M.) and
Department of
Neurology (M.P.-H.), University of Kuopio, FIN-70211 Kuopio, Finland,
Department of Anatomy, Tampere University Medical School, FIN-33101
Tampere, Finland (M.P.-H.),
Department of Molecular and Cellular
Physiology (R.E.L., B.K.K.),
Howard Hughes Medical Institute (G.S.B.,
B.K.K.),
Department of Pediatrics (G.S.B.), and
Division of
Cardiovascular Medicine (B.K.K.), Stanford University, Stanford,
California 94305
2-Adrenergic receptors (2-ARs) regulate
many physiological functions and are targets for clinically important
antihypertensive and anesthetic agents. Three human and mouse genes
encoding 2-AR subtypes (2A,
2B, and 2C) have been cloned. We
investigated the involvement of the 2C-AR in
2-adrenergic pharmacology by applying molecular genetic
techniques to alter the expression of 2C-AR in mice. The
effects of dexmedetomidine, a subtype-nonselective 2-AR
agonist, on monoamine turnover in brain and on locomotor activity were
similar in mice with targeted inactivation of the 2C-AR
gene and in their controls, but the hypothermic effect of the
2-AR agonist was significantly attenuated by the
receptor gene inactivation. Correspondingly, another strain of
transgenic mice with 3-fold overexpression of 2C-AR in
striatum and other brain regions expressing 2C-AR showed
normal reductions in brain monoamine metabolism and locomotor activity
after dexmedetomidine, but their hypothermic response to the
2-AR agonist was significantly accentuated. The
hypothermic effect of 2-AR agonists thus seems to be
mediated in part by 2C-AR. Some small but statistically significant differences between the strains were also noted in brain
dopamine metabolism. Lack of 2C-AR expression was linked with reduced levels of homovanillic acid in brain, and mice with increased 2C-AR expression had elevated concentrations
of the dopamine metabolite compared with their controls.
This article has been cited by other articles:
|
|
 |
|
  A.-M. Linden, C. Sandu, M. I. Aller, O. Y. Vekovischeva, P. H. Rosenberg, W. Wisden, and E. R. Korpi TASK-3 Knockout Mice Exhibit Exaggerated Nocturnal Activity, Impairments in Cognitive Functions, and Reduced Sensitivity to Inhalation Anesthetics J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 924 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G KARKOULIAS, O MASTROGIANNI, I ILIAS, A LYMPEROPOULOS, S TARAVIRAS, N TSOPANOGLOU, N SITARAS, and C.S FLORDELLIS Alpha 2-Adrenergic Receptors Decrease DNA Replication and Cell Proliferation and Induce Neurite Outgrowth in Transfected Rat Pheochromocytoma Cells Ann. N.Y. Acad. Sci., November 1, 2006; 1088(1): 335 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Paris, J. Mantz, P. H. Tonner, L. Hein, M. Brede, and P. Gressens The Effects of Dexmedetomidine on Perinatal Excitotoxic Brain Injury are Mediated by the {alpha}2A-Adrenoceptor Subtype Anesth. Analg., February 1, 2006; 102(2): 456 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Szot, S. S. White, J. L. Greenup, J. B. Leverenz, E. R. Peskind, and M. A. Raskind Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer's Disease and Dementia with Lewy Bodies J. Neurosci., January 11, 2006; 26(2): 467 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H J Kim, M Camilleri, P J Carlson, F Cremonini, I Ferber, D Stephens, S McKinzie, A R Zinsmeister, and R Urrutia Association of distinct {alpha}2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders Gut, June 1, 2004; 53(6): 829 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Feleder, V. Perlik, and C. M. Blatteis Preoptic {alpha}1- and {alpha}2-noradrenergic agonists induce, respectively, PGE2-independent and PGE2-dependent hyperthermic responses in guinea pigs Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2004; 286(6): R1156 - R1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Zuideveld, J. Rusic-Pavletic, H. J. Maas, L. A. Peletier, P. H. Van der Graaf, and M. Danhof Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1130 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Tan, M. H. Wilson, L. B. MacMillan, B. K. Kobilka, and L. E. Limbird Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists PNAS, September 17, 2002; 99(19): 12471 - 12476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Philipp, M. Brede, and L. Hein Physiological significance of alpha 2-adrenergic receptor subtype diversity: one receptor is not enough Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R287 - R295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Fairbanks, L. S. Stone, K. F. Kitto, H. O. Nguyen, I. J. Posthumus, and G. L. Wilcox alpha 2C-Adrenergic Receptors Mediate Spinal Analgesia and Adrenergic-Opioid Synergy J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 282 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Viramontes, A. Malcolm, M. Camilleri, L. A. Szarka, S. McKinzie, D. D. Burton, and A. R. Zinsmeister Effects of an alpha 2-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans Am J Physiol Gastrointest Liver Physiol, December 1, 2001; 281(6): G1468 - G1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, A. Dekeyne, A. Newman-Tancredi, D. Cussac, V. Audinot, G. Milligan, D. Duqueyroix, S. Girardon, J. Mullot, J. A. Boutin, et al. S18616, a Highly Potent, Spiroimidazoline Agonist at alpha 2-Adrenoceptors: I. Receptor Profile, Antinociceptive and Hypothermic Actions in Comparison with Dexmedetomidine and Clonidine J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1192 - 1205. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, F. Lejeune, A. Gobert, M. Brocco, A. Auclair, C. Bosc, J.-M. Rivet, J.-M. Lacoste, A. Cordi, and A. Dekeyne S18616, a Highly Potent Spiroimidazoline Agonist at alpha 2-Adrenoceptors: II. Influence on Monoaminergic Transmission, Motor Function, and Anxiety in Comparison with Dexmedetomidine and Clonidine J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1206 - 1222. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Kable, L. C. Murrin, and D. B. Bylund In Vivo Gene Modification Elucidates Subtype-Specific Functions of alpha 2-Adrenergic Receptors J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 1 - 7. [Abstract] [Full Text]
|
|
|
|
|
|
T. Olli-Lahdesmaki, J. Kallio, and M. Scheinin Receptor Subtype-Induced Targeting and Subtype-Specific Internalization of Human alpha 2-Adrenoceptors in PC12 Cells J. Neurosci., November 1, 1999; 19(21): 9281 - 9288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Altman, A. U. Trendelenburg, L. MacMillan, D. Bernstein, L. Limbird, K. Starke, B. K. Kobilka, and L. Hein Abnormal Regulation of the Sympathetic Nervous System in alpha 2A-Adrenergic Receptor Knockout Mice Mol. Pharmacol., July 1, 1999; 56(1): 154 - 161. [Abstract] [Full Text]
|
|
|
|
|
|
W. Zhang, V. Klimek, J. T. Farley, M.-Y. Zhu, and G. A. Ordway alpha 2C Adrenoceptors Inhibit Adenylyl Cyclase in Mouse Striatum: Potential Activation by Dopamine J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1286 - 1292. [Abstract] [Full Text]
|
|
|
|
|
|
P. Chopin, F. C. Colpaert, and M. Marien Effects of Alpha-2 Adrenoceptor Agonists and Antagonists on Circling Behavior in Rats with Unilateral 6-Hydroxydopamine Lesions of the Nigrostriatal Pathway J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 798 - 804. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. R. PICCIOTTO and K. WICKMAN Using Knockout and Transgenic Mice to Study Neurophysiology and Behavior Physiol Rev, October 1, 1998; 78(4): 1131 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Björklund, J. Sirviö, J. Puoliväli, J. Sallinen, P. Jäkälä, M. Scheinin, B. K. Kobilka, and P. Riekkinen Jr. alpha 2C-Adrenoceptor-Overexpressing Mice Are Impaired in Executing Nonspatial and Spatial Escape Strategies Mol. Pharmacol., September 1, 1998; 54(3): 569 - 576. [Abstract] [Full Text]
|
|
|
|
|
|
J. Sallinen, A. Haapalinna, T. Viitamaa, B. K. Kobilka, and M. Scheinin Adrenergic alpha 2C-Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice J. Neurosci., April 15, 1998; 18(8): 3035 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. ROHRER and B. K. KOBILKA G Protein-Coupled Receptors: Functional and Mechanistic Insights Through Altered Gene Expression Physiol Rev, January 1, 1998; 78(1): 35 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Small, S. L. Forbes, F. F. Rahman, K. M. Bridges, and S. B. Liggett A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human alpha 2C-Adrenergic Receptor Confers Impaired Coupling to Multiple Effectors J. Biol. Chem., July 21, 2000; 275(30): 23059 - 23064. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
